GLP-1

News

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.

News

A man drunken on vodka lies in the grass

Altimmune alcohol use disorder drug hits the mark in phase 2

Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.

News

Lilly plans Q1 2027 filing for obesity triple retatrutide

Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.

News

Novo's Wegovy pill cleared for weight loss in EU

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

News

Major trial launched to explore GLP-1 benefit in dementia

A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.

News

Kailera's big obesity reveal puts pressure on shares

Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

Altimmune alcohol use disorder drug hits the mark in phase 2

Lilly plans Q1 2027 filing for obesity triple retatrutide

Novo's Wegovy pill cleared for weight loss in EU

Major trial launched to explore GLP-1 benefit in dementia

Kailera's big obesity reveal puts pressure on shares

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks